IDH assay facilitates timelier leukemia treatment: Rong He, M.D. - Insights
In this test-specific episode of the "Answers From the Lab" podcast, Rong He, M.D., explains how Mayo Clinic Laboratories' IDHQ test improves upon next generation sequencing for assessing AML treatment options.
August 2023 - Biochemical Genetics - Insights
This "Pathways" program provides a Clinical Pathology case that includes a history, potential answers, rationale, and relevant references. This case sub-specialty is Biochemical Genetics.
Sudden cardiac death and episodes of fainting and seizures from long QT syndrome are significantly lower than previously thought when patients are diagnosed and treated at a specialty center dedicated to the treatment of genetic heart...
MML Prenatal Testing Brochure - MC2775-111
MML Prenatal Testing Brochure - PRENATAL TESTING COMPREHENSIVE SCREENING DIAGNOSTIC TESTING FETAL ABNORMALITIES WOMEN HEALTH CLINIC PRENATAL TESTING
Psychotropic PGx Panel for Drug Treatment Optimization [Test in Focus] - Insights
Ann Moyer, M.D., Ph.D. gives an overview of this new test available through Mayo Clinic Laboratories. She discusses when this testing should be ordered, how this testing improves upon other testing approaches, and what clinical action can...
Mayo Clinic Laboratory and pathology research roundup: April 12 - Insights
This Feature Includes: Latent pulmonary vascular disease may alter the response to therapeutic atrial shunt device in heart failure.
Pathways Case Studies: February 2022 - Insights
This "Pathways" program provides Anatomic and Clinical Pathology cases that include a history, potential answers, rationale, and relevant references. Cases for February include the following sub-specialties: Clinical Biochemistry, Bone and...
In this month’s “Hot Topic,” Robin Patel, M.D., discusses the FilmArray meningitis/encephalitis (ME) panel, describing the panel, her experience with it, and an algorithm for its use.
Communiqué Archives - Insights
Skip to Content MayoACCESS MayoLINK...
Find out more about UBA1Q, a quantitative droplet digital polymerase chain reaction (ddPCR) assay that targets seven possible mutations that can occur in the UBA1 gene and help identify VEXAS syndrome.